months (immediate post-CVR) and 3–6 months (sustained post-CVR) relative to the 1-month visit (pre-CVR).

**Results** Between April 2016 to November 2017, 151 women (median age 27 y) were enrolled and 122 (81.9%) initiated CVR; 30 (24.6%) were HIV-infected. Six women (4.9%) had BV at the pre-CVR visit. Over a median duration of follow-up of 4.7 months, BV incidence/recurrence was 10.2% at the immediate post-CVR visit and 7.1% over the sustained post-CVR visits. In a model combining CVR arms that adjusted for age and unprotected sex, we observed a non-significant increase in BV incidence/recurrence immediately post-CVR (adjusted OR = 2.5 (0.9, 7.2), after which BV returned to a level comparable to CVR insertion (AOR=1.2 (0.8, 1.9).

**Conclusion** Cumulative incidence of recurrent BV in the 6 months after CVR initiation is lower than historically reported rates in prospective studies, which are typically in ≥50% range. Concomitant incidence of vulvovaginal candidiasis, however, requires further study. The CVR should be considered for potential long-term optimization of the vaginal environment.

**Disclosure** No significant relationships.

---

**P370 PREVALENCE OF CHLAMYDIA, GONORRHOEA, M. GENITALITUM AND T. VAGINALIS IN THE GENERAL POPULATION OF SLOVENIA, 2016–2017**

Irena Klavš*, 1Maja Milavec, 2Tanja Kustec, 2Marta Gregl Vitek, 2Darja Lavtar, 2Metka Zaletet, 3Andrej Golle, 3Darja Duh, 3Tjaža Zohar Crennik, 5National Institute of Public Health, Communicable Diseases Centre, Ljubljana, Slovenia; 4National Institute of Public Health, Ljubljana, Slovenia; 5National Laboratory of Health Environment and Food, Maribor, Slovenia

10.1136/sextrans-2019-sti.472

**Background** To inform sexually transmitted infections (STIs) prevention and control, objective of the second National Survey of Sexual Lifestyles, Attitudes and Health was to estimate the prevalence of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Mycoplasma genitalium* and *Trichomonas vaginalis* infections.

**Methods** A survey of the general population aged 18–49 was conducted in 2016–2017. We used stratified two-stage probability sampling from the Central Population Registry. Survey respondents were invited to contribute first void urine specimens for testing for *C. trachomatis* and unlinked anonymous testing for other STIs to obtain population prevalence estimates. Specimens were tested for *C. trachomatis* with specific real time PCR targeting both cryptic plasmid and bacterial chromosome. Positive results were confirmed by Sanger sequencing of the amplicon. Other STIs were detected by commercially available multiplex PCR (FTD Urethritis plus, fast-track Diagnostics). To avoid false negative results, the human house keeping gene was amplified in all tested samples.

**Results** Urine specimens from 452 men and 635 women (56.4% of all survey respondents) were tested for chlamydia. Overall weighted prevalence was 0.5% (95% CI 0.1% to 1.4%) in men and 1.7% (95% CI 0.9% to 3.1%) in women. Age-specific prevalence was the highest among 18–24 years old (men: 2.8%; 95%CI 0.9% to 8.5%; women: 4.7%; 95% CI 1.6% to 10.7%). Urine specimens from 430 men and 593 women (53.0% of all survey respondents), were tested for other STIs. No infections with *N. gonorrhoeae* were found. Weighted prevalence estimate for *M. genitalium* was 0.5% (95% CI 0.2% to 1.5%) in men and 0.3% (95% CI 0.0% to 0.9%) in women. Parasite *T. vaginalis* was detected in one woman only. Corresponding weighted prevalence was 0.2% (95% CI 0.0%–0.9%).

**Conclusion** The prevalence of *C. trachomatis* infection in the general population of Slovenians aged 18–24 was substantial. The other three STIs were relatively rare.

**Disclosure** No significant relationships.

---

**P371 EFFECT OF METRONIDAZOLE TREATMENT ON RECURRENT AND PERSISTENT BACTERIAL VAGINOSIS: A PILOT STUDY**

1Makella Coudray*, 2Daniel Ruiz-Perez, 3Brett Colbert, 4Karl Krupp, 5Hansi Kumari, 2Giri Narasimhan, 6Kalai Mathee, 3Purnima Madhivanan. 1Florida International University, Department of Epidemiology, Robert Stempel College of Public Health, Miami, USA; 2Florida International University, Bioinformatics Research Group, Miami, USA; 3Florida International University, Department of Biological Sciences, College of Arts and Sciences, Miami, USA; 4Florida International University, Department of Health Promotion and Disease Prevention, Robert Stempel College of Public Health, Miami, USA; 5Florida International University, Biomolecular Sciences Institute, Miami, USA

10.1136/sextrans-2019-sti.473

**Background** This study aims to investigate the effect of metronidazole for the treatment of recurrent and persistent bacterial vaginosis (BV).

**Methods** Stored vaginal swabs of 80 African American (AA) women were randomly selected from a previously conducted clinical trial for this pilot study. Women with BV were treated with metronidazole. Vaginal smears were categorized by the Nugent score (NS) [0–3; normal; 4–6; intermediate state; 7–10, BV]. Women were classified as recurrent BV (RBV), persistent BV (PBV) or no BV based on three consecutive NS. RBV occurs when an episode of BV occurs after successful treatment of a prior episode. PBV occurs in instances when BV treatment fails to restore healthy *Lactobacillus* levels. All women were asymptomatic for BV at baseline and followed every two months for four months.

**Results** After four months, 22.5% (CI: 13%, 32%) of women did not have BV, 7.5% (CI: 2%, 13%) had RBV and 70% had PBV (CI: 60%, 80%). 30% of treated women did not have BV compared to 15% of untreated women (p=0.18). BV recurred among 12.5% of treated women and 2.5% of untreated women (p=0.2). BV persisted among 57.5% of treated women and 82.5% of untreated women (p=0.03). Women that were treated had 0.33 decreased odds (95%CI: 0.12, 0.92, p<0.05) of having PBV as compared to untreated women. The mean age was 21.4 years (SD: 2.11 years). Prior antibiotic use among those who were previously treated for BV, 60% were treated more than five times. Douching was reported by 49% of the sample.

**Conclusion** These preliminary findings suggest, standard BV treatment may not be effective among women with RBV or adherence to treatment may be low among women with asymptomatic BV.

**Disclosure** No significant relationships.